Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Translation in Brief

Lighting up the DYRK

How inhibiting DYRK1A can promote neurogenesis and help treat Down syndrome

Winnie Pong and Mark Zipkin, Staff Writers
November 16, 2017 8:27 PM UTC

Kyoto University researchers have described a DYRK1A inhibitor that could treat neuronal deficits in Down syndrome with fewer side effects than other inhibitors of the kinase -- but neurology company NeuroNascent Inc. suggests the safety of the strategy remains an open question.

Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) is located in a region of chromosome 21 known to drive Down syndrome. The gene is overexpressed in adults with the condition. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Kyoto University

ManRos Therapeutics S.A.

Neuronascent Inc.

Pharmasum Therapeutics A/S